Ngl Fine-chem Ltd. · NSE:NGLFINE
Ngl Fine-chem — Q4 FY23 Earnings Presentation
19 slides from Ngl Fine-chem's earnings presentation, May 18, 2023
Slide 1: Cover letter to stock exchanges
Regd. Office 301, E – Square, Subhash Road, Vile Parle East, Mumbai 400057 Maharashtra, India. Tel.: (+91 22) 40842222, Fax: (+91 22) 2610 8030, Email: info@nglfinechem.com CIN L24110MH1981PLC025884,Website www.nglfinechem.com May 18, 2023 To, Listing Department, Listing Department, The BSE Limited
Slide 2: Investor Presentation Q4FY23 & FY23
NGL Fine-Chem Limited INVESTOR P R ES EN TATI ON Q4FY23 & FY23
Slide 3: Disclaimer
Disclaimer This investor presentation has been prepared by NGL Fine-Chem Limited and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be d
Slide 4: Inside This Presentation
Inside This Presentation Pg. No. Pg. No. 04 11 Q4FY23 & Over view, FY23 Key Strengths Highlights and Strategy Pg. No. 16 Historical Financial Performance
Slide 5: Q4FY23 & FY23 Highlights
01 Q4FY23 & FY23 Highlights 05 M A N A G E M E N T C O M M E N TA R Y 06 Q U A R T E R LY O P E R AT I O N A L M E T R I C S 07 F U L L Y E A R O P E R AT I O N A L M E T R I C S 08 S U M M A R Y O F P R O F I T A N D LO S S S TAT E M E N T 09 SUMMARY OF BAL ANCE SHEET 10 S U M M A R Y O F C A S H F
Slide 6: Management Commentary
MANAGEMENT COMMENTARY Dear Shareholders, W e a n ti ci p a te th a t th e o p er a ti n g en v i r o n men t wi l l I a m p l ea s ed to p r o v i d e y o u wi th a n u p d a te o n th e co n ti n u e to p o s e ch a l l en g es fo r th e n ext two q u a r ter s . p er fo r ma n ce o f N G L Fi n e
Slide 7: Quarterly Operational Metrics
Quarterly Operational Metrics SEGMENTAL REVENUE MIX PRODUCT CONCENTRATION PARTICULARS Q4FY22 Q3FY23 Q4FY23 PARTICULARS Q4FY22 Q3FY23 Q4FY23 ANIMAL API 85% 81% 81% TOP 3 PRODUCTS 35% 39% 41% HUMAN API 9% 5% 3% TOP 5 PRODUCTS 51% 53% 58% INTERMEDIATES 5% 8% 11% TOP 10 PRODUCTS 78% 77% 78% FORMULATIONS
Slide 8: Full Year Operational Metrics
Full Year Operational Metrics SEGMENTAL REVENUE MIX PRODUCT CONCENTRATION PARTICULARS FY21 FY22 FY23 PARTICULARS FY21 FY22 FY23 ANIMAL API 76% 81% 83% TOP 3 PRODUCTS 44% 37% 34% HUMAN API 7% 7% 5% TOP 5 PRODUCTS 57% 52% 47% INTERMEDIATES 9% 9% 7% TOP 10 PRODUCTS 79% 76% 72% FORMULATIONS 8% 3% 5% GEO
Slide 9: Summary of Profit and Loss Statement
Summary of Profit and Loss Statement ₹ IN CRORES PARTICUL ARS Q4FY22 Q3FY23 Q4FY23 Q-o-Q Y-o-Y FY22 FY23 Y-o-Y REVENUE FROM OPERATIONS 84.06 71.93 73.89 2.72% -12.10% 317.50 278.08 -12.42% OTHER INCOME 2.98 0.69 2.10 204.35% -29.53% 10.68 5.53 -48.22% TOTAL REVENUE 87.04 72.62 75.99 4.64% -12.70% 32
Slide 10: Summary of Balance Sheet
Summary of Balance Sheet ₹ IN CRORES PARTICUL ARS FY22 FY23 SHAREHOLDERS FUND 203.22 222.55 NON CURRENT LIABILITIES 8.06 6.23 LONG TERM BORROWINGS 3.44 2.07 CURRENT LIABILITIES 65.65 58.30 SHORT TERM BORROWINGS 23.43 28.41 TOTAL EQUITY AND LIABILITIES 276.93 287.08 NON CURRENT ASSETS 103.44 124.43 N
Slide 11: Summary of Cash Flow Statement
Summary of Cash Flow Statement ₹ IN CRORES PARTICUL ARS FY22 FY23 CASH FLOW FROM OPERATING ACTIVITIES 13.83 35.29 CASH FLOW FROM INVESTING ACTIVITIES -14.21 -27.02 CASH FLOW FROM FINANCING ACTIVITIES -1.08 -1.08 NET CASH FLOW -1.46 7.18 CASH AT THE BEGINNING OF YEAR 2.1 0.64 CASH AT THE END OF YEAR
Slide 12: Overview, Strengths and Strategy
02 Overview, Strengths and Strategy 12 L E A D I N G A N I M A L H E A LT H C O M PA N Y 13 LEADERSHIP IN VETERINARY API SEGMENT 14 S TAT E - O F - T H E - A R T M A N U FA C T U R I N G C A PA B I L I T I E S 15 S T R AT E G Y F O R N E X T L E G O F G R O W T H
Slide 13: Leading Animal Health Company
Leading Animal Health Company COMPREHENSIVE MARKET MANUFACTURING LARGE GLOBAL LONG STANDING PRODUCT LEADERSHIP EXCELLENCE PRESENCE CUSTOMER PORTFOLIO IN VETERINARY API RELATIONSHIPS • 26 APIs (24 Veterinary • Leadership in top • 3 state of the art • 45+ countries across • ~400 customers APIs, 2 Huma
Slide 14: Leadership in Veterinary API Segment
Leadership in Veterinary API Segment REVENUE FROM VETERINARY CUSTOMER & PRODUCT Strong controls of processes with 95% in-house manufacturing and API SEGMENT (₹ IN CRORES) 15% CAGR CONCENTRATION (OF SALES FY23) backward integrated facilities leading to cost competitiveness FY23 225 CUSTOMER PRODUCT F
Slide 15: State-of-the-art Manufacturing Capabilities
State-of-the-art Manufacturing Capabilities HIGHLIGHTS 3 manufacturing facilities located at Tarapur & Navi 10,000 m 2 102 m 3 194 m 3 AREA OF GLASS-LINED STAINLESS STEEL Mumbai, Maharashtra, MANUFACTURING REACTORS REACTORS designed to meet the FACILITIES requirements of regulatory agencies and are
Slide 16: Strategy for next leg of growth
Strategy for next leg of growth BROWNFIELD EXPANSION • Completed expansion in subsidiary Macrotech ONGOING INITIATIVES • Additional capacities of intermediates TO INCREASE a • Commercial production started CAPACITIES TO MEET GROWING DEMAND GREENFIELD EXPANSION AT TARAPUR • 50% capacity expansion wit
Slide 17: Historical Financial Performance
03 Historical Financial Performance 17 ROBUST FINANCIAL PERFORMANCE
Slide 18: Robust Financial Performance
Robust Financial Performance REVENUE EBITDA PAT (₹ IN CRORES) (₹ IN CRORES) (₹ IN CRORES) FY23 278 FY23 34 FY23 21 FY22 318 FY22 68 FY22 50 FY21 258 FY21 80 FY21 57 FY20 152 FY20 19 FY20 8 FY19 153 FY19 32 FY19 20 0 50 100 150 200 250 300 350 0 10 20 30 40 50 60 70 80 90 0 10 20 30 40 50 60 GROSS MA
Slide 19: Thank You
FOR ANY FURTHER INFORMATION, PLEASE CONTACT Thank You Pallavi Pednekar Abhishek Mehra NGL FINE-CHEM TIL ADVISORS PRIVATE LIMITED LIMITED cs@nglfinechem.com abhishek@theinvestmentlab.in +91 22 40842222 +91 95588 14500 Corporate Office 301, E-square, Subhash Road, Vile Parle (East), Mumbai - 400057, M